ArticleScientific reports2025
Bardoxolone methyl (Bard)-mediated strong suppression of calcium oxalate crystal formation in renal crystal recurrence model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The oxidative stress response during renal crystal recurrence and the dynamics of calcium oxalate (CaOx) crystal formation and clearance in a glyoxylate (GOX)-induced mouse model were examined. CaOx crystals gradually accumulated during five consecutive days of GOX administration, decreased by half in the ten days after administration, and required five weeks for near-complete clearance. HO-1 expression was strongly induced by the initial GOX administration through Nrf2 activation but diminished on continuing the administration. When GOX was readministered after a 10-day interval, HO-1 induction was minimal; however, after a 5-week interval, HO-1 expression returned to its initial levels. Readministration of GOX after crystal clearance resulted in reduced crystal formation and individual differences in crystal volume compared with the initial episode. Preadministration of bardoxolone methyl (Bard), a potent Nrf2 activator, significantly suppressed recurrent CaOx crystal formation. These findings strongly suggest the existence of an interaction between oxidative stress responses and renal crystal recurrence, highlighting the potential of Nrf2 activation as a preventive strategy for recurrent stone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.